Although in-stent restenosis (ISR) is not on the radar of operators as much as it once was, the proportion of PCIs performed for it has remained steady over time in the United States, accounting for ...

In-stent restenosis (ISR) complicates revascularization in the coronary and peripheral arteries. Apolipoprotein A1 (apoA1), the principal protein component of HDL possesses inherent ...

The present study was aimed to investigate whether Gensini score or SYNTAX score was a valuable tool to predict in-stent restenosis (ISR) in coronary artery disease (CAD) patients with drug-eluting ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

For coronary in-stent restenosis (ISR), drug-coated balloons (DCB) appear to perform just as well over the long term as thin-strut drug-eluting stents after accounting for differences in patient ...

Insertion of stents that release the drug paclitaxel to treat stenosis within an implanted bare-metal stent in a coronary artery reduces the risk of subsequent re-narrowing within the stent, when ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to a control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA ...

For interventionalists hoping that a new generation of coronary balloons might improve treatment of in-stent restenosis (ISR), contemporary registry data were encouraging. In a propensity ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

InterVene’s Recana, a mechanical thrombectomy catheter designed to address venous in-stent restenosis (ISR) and clear vessel obstructions, has received 510(k) clearance from the US Food and Drug ...